Independent experts cast doubt on OncoMed's cancer drug

(Reuters) - OncoMed Pharmaceuticals Inc lost nearly half its market value after independent investigators informed the company that its pancreatic cancer drug was unlikely to meet the main goal in a mid-stage study.